Anti-Jk3 -- The Other Kidd

No not a child! Kidd!
No not a child! Kidd!
Kidd Genesis --- Jk-Null Phenotype and Anti-Jk3

The discovery of the Jk-null phenotype, denoted as JK(a-b-), traces back to 1959 when a woman developed jaundice following a blood transfusion. Her serum contained an unusual antibody that recognized both Jka and Jkb antigens. This antibody was termed anti-Jk3.

Genetics and Population Prevalence

The Jk-null phenotype is exceptionally rare in most populations but somewhat more common in Polynesians, with a frequency of 0.9%. It is inherited as a recessive trait, implying that both parents must carry the mutated gene for a child to manifest this phenotype. Various mutations have been identified, with splice site mutations causing loss of exon 6 in Polynesians, and even different genetic mutations seen in the Finnish population.

Clinical Implications of Anti-Jk3

Hemolytic Disease of the Newborn (HDN)

Once immunized, individuals with the Jk-null phenotype can produce anti-Jk3 antibodies, which can result in HDN in subsequent pregnancies if the baby carries either Jka or Jkb antigen.

Hemolytic Transfusion Reactions

Anti-Jk3 can cause severe hemolytic transfusion reactions, both immediate and delayed, as it reacts against both Jka and Jkb. This makes finding compatible blood for transfusion exceedingly difficult for these individuals, as they can only receive JK(a-b-) blood.

The Physiology of Kidd Glycoprotein

The SLC14A1 gene encodes the Kidd glycoprotein, a significant urea transporter in red blood cells (RBCs). This transporter helps maintain osmotic stability by facilitating urea's rapid movement in and out of RBCs. In the kidney, this protein concentrates urine by allowing the medulla to maintain high urea concentrations.

In individuals with the Jk-null phenotype, urea transport across the RBC membrane is about 1,000 times slower than in those with typical RBCs. Despite this, the absence of the Kidd glycoprotein does not seem to have a substantial disease association. These RBCs maintain normal shape and lifespan, and the individuals show no other significant health issues besides an inability to maximally concentrate urine.

The Role of 2M Urea in Anti-Jk3 Characterization

In the domain of immunohematology, 2M urea serves as a powerful tool for antibody identification, particularly for Kidd antibodies. The Kidd blood group system antibodies, including anti-Jk3, are known for their sensitivity to 2M urea, which helps in their identification and characterization.

  1. Antibody Discrimination: Treatment of reagent RBCs with 2M urea can help distinguish Kidd antibodies from other blood group antibodies. If a suspected anti-Jk3 antibody retains its reactivity after 2M urea treatment, it is likely not a Kidd antibody. Conversely, if the reactivity is diminished or abolished, it suggests that the antibody is indeed anti-Jk3.

  2. Continuous Monitoring: For patients known to possess anti-Jk3, periodic reactivity checks can be performed using 2M urea. This is particularly important when planning for transfusions or transplants, as the presence of anti-Jk3 significantly narrows the range of compatible donor blood.

  3. Research Utility: In a more advanced research setting, 2M urea could be employed to study the thermodynamics and kinetics of anti-Jk3 binding to Jka and Jkb antigens. Such studies could offer insights into the mechanisms underlying the formation and specificity of anti-Jk3.

Anti-Jk3 is a clinically significant but rare antibody that primarily occurs in individuals with the Jk-null phenotype. Its presence poses challenges in transfusion medicine and maternal-fetal medicine. 2M urea plays a crucial role in the antibody's identification and ongoing monitoring. While the Kidd glycoprotein has a vital role in urea transport, its absence in Jk-null individuals does not cause disease, but it does lead to a significantly increased risk of hemolytic reactions in the context of transfusions and pregnancy. Therefore, understanding the complexities surrounding anti-Jk3 is crucial for better clinical management and future research.

Anti-PP1Pk and Pregnancy

Pregnacy and Anti-PP1Pk. Not a good mix
In women with a rare p phenotype, which lacks P, P1, and Pk red cell antigens, there is a presence of naturally occurring anti-PP1Pk antibodies, previously referred to as Anti-Tja. These antibodies have been closely associated with recurrent miscarriages, particularly in the first half of pregnancy. The p phenotype is exceedingly rare, with an estimated global prevalence of around 5.8 in one million people.

When a woman with this phenotype becomes pregnant, it's vital to manage the titers of the anti-PP1Pk antibodies, as they can pose risks to the pregnancy. In practice, this often involves treatments like plasma exchange therapy or double-filtration plasmapheresis. These treatments aim to reduce the concentration of these antibodies to safer levels (between 1:16 and 1:32) as a way to mitigate the risks.

However, the necessity of these aggressive treatments can depend on the woman's specific medical situation. For instance, some cases have shown that when these antibody titers are naturally low and well-monitored, it might be possible to manage the pregnancy without resorting to treatments like plasmapheresis. Monitoring usually involves bi-weekly checks of antibody titers.

In addition to managing the antibody levels, some patients are also put on medications like prednisolone and low-molecular-weight heparin (LMWH). While the exact role and effectiveness of these medications in such cases are still under debate, they are known for their anti-inflammatory and immunosuppressive properties.

The P, P1, and Pk antigens and the associated antibodies are part of broader blood group systems involving different glycosyltransferases necessary for their synthesis. The absence of these antigens, which gives rise to the p phenotype, is a result of inactivating mutations in the A4GALT1 gene located in chromosome 22q13.2. This gene is responsible for synthesizing 4-α-galactosyltransferase, the enzyme necessary for producing Pk, P, and P1 antigens.

Interestingly, these antibodies can exist in various forms, including regular IgM, irregular or regular IgG types, or a combination. The cytotoxic effects seem primarily to belong to the IgG3 subclass. These antibodies can cross the placental barrier and are known to activate complement, contributing to antibody-mediated cytotoxicity.

Identification of PP1Pk in hospital blood banks 

The presence of anti-PP1Pk antibodies would indeed yield results that could resemble panagglutination because every cell in the panel would likely test positive. This is due to the high prevalence of P, P1, and Pk antigens in the general population, making almost all donor cells susceptible to agglutination by the anti-PP1Pk antibodies. Therefore, distinguishing anti-PP1Pk from other causes of panagglutination would require specialized testing, often involving the use of cells specifically lacking these antigens or additional serological techniques. Hospital systems would be wise to send reference testing on patients, especially women of childbearing age, to determine the etiology of reactivity. 

Finding PP1Pk RBCs

Finding compatible blood products for individuals with anti-PP1Pk antibodies is an incredibly challenging task given the rarity of donors lacking P, P1, and Pk antigens. Standard blood banks are not equipped to handle this level of specificity in their inventories.

In these cases, medical professionals often have to resort to specialized approaches. The Rare Donor Program may be employed to find a compatible donor, although the rarity of such donors makes this a challenging and time-consuming endeavor. Even within this program, finding a matching donor can be like finding a needle in a haystack, given that these antigens are present in more than 99.9% of the general population.

An alternative approach could be the use of frozen blood products, assuming they have been previously identified and stored for this specific purpose. However, this is often not a guarantee, and there may be logistical and stability issues associated with using frozen products.

Due to these extreme difficulties, patients are sometimes encouraged to recruit potential donors from within their familial or community circles, although this too can be a long shot. If found, such donors can be invaluable, not only for the individual patient in need but also for adding to the database of rare donors.

Given these challenges, preemptive steps like autologous blood donation (where the patient donates blood for their own future use) may be considered, especially if a planned surgical procedure or childbirth is anticipated.

I actually had a case of a young pregnant woman with an Anti-PP1Pk. We notified our Blood Center several weeks prior to her scheduled delivery date that we would need two units of blood on hold as agreed upon by OB and Pathology. Come time for delivery, we had nothing on our shelves. They're search came up with nothing all that time, but thankfully mom delivered, with no complications! I shudder to think what would happen if things didn't go as planned!

Parvovirus B19 Receptor and PP1PK System

Parvovirus B19 primarily infects red blood cells by binding to the P antigen, which serves as its cellular receptor. The P antigen is a globoside and is essentially the foundation molecule for the other antigens (P1 and Pk) in this system. Individuals lacking the P antigen (rare but possible) are resistant to parvovirus B19 infection, which is known for causing diseases like erythema infectiosum (fifth disease) in children and temporary aplastic crises in adults with chronic hemolytic anemia.

Platelet Refractoriness

Platelet refractoriness is a significant challenge in transfusion medicine, referring to the failure of a patient to achieve the expected increase in platelet count following a platelet transfusion. This phenomenon has both immune and non-immune causes and can complicate the clinical management of patients, particularly those with hematologic malignancies or undergoing stem cell transplantation.

Causes of Platelet Refractoriness

Immune-Mediated Causes

1. Alloimmunization to HLA Class I Antigens
Platelets can be troublesome!

Human Leukocyte Antigens (HLA) are complex molecules that serve as the primary determinants for tissue compatibility in humans. Class I HLA molecules are present on almost all nucleated cells, including platelets. In the setting of platelet transfusions, the recipient's immune system can recognize these HLA antigens as foreign if they are not already present in the patient, leading to an immune response.

Mechanism of Alloimmunization

  • When a patient receives platelet transfusions from different donors, each transfusion episode carries a risk of introducing platelets with foreign HLA antigens. The immune system, recognizing these as non-self, can produce antibodies specific to these HLA antigens. Once alloimmunized, the recipient's plasma will contain these antibodies, which are primed to neutralize any subsequent transfusions containing platelets with the same or similar HLA antigens.


    The development of HLA antibodies leads to rapid clearance of transfused platelets from the circulation, resulting in suboptimal or negligible increases in platelet counts after transfusion. This means that even though the patient is receiving platelets, the expected improvement in clotting capability is not achieved, putting the patient at risk of bleeding complications.

    Diagnostic Strategies

    HLA Antibody Screening: This involves testing the patient’s serum for the presence of HLA antibodies. High-resolution assays like Luminex-based techniques can identify specific HLA antibodies, giving a more targeted approach to donor selection.

    Crossmatching: Before a transfusion, the donor's platelets can be crossmatched with the recipient's serum to test for compatibility.

Management Options

HLA-Matched Platelets: The ideal strategy is to transfuse platelets that are HLA-matched to the recipient. This minimizes the risk of antibody-mediated platelet destruction.

Cross-Matched Platelets: If an exact HLA match is not available, platelets that have been cross-matched to be compatible with the recipient can also be an option, although not commonly performed.

HLA-Desensitization: In extreme cases, immunosuppressive medications or plasmapheresis can be used to reduce the levels of HLA antibodies, although these options have their own set of risks and limitations.

Challenges in Clinical Practice

Donor Pool: Finding a suitable donor is often challenging and becomes progressively harder with each transfusion episode that leads to additional alloimmunization.

Logistical Constraints: HLA-matched platelets may not always be readily available and require coordination between different blood banks and registries.

Ethnic Variability: HLA types can vary between different ethnic groups, complicating matching in ethnically diverse populations.

Cost: High-resolution HLA typing and antibody screening tests are expensive and may not be feasible in all healthcare settings.


HLA-Matched Platelets


In this approach, the aim is to find a donor whose HLA antigens closely match those of the recipient. This reduces the chance of an immune response against the transfused platelets, leading to a more effective transfusion.


  • Comprehensive HLA typing is performed for both the recipient and potential donors.
  • Sophisticated matching algorithms may be used to find the closest possible match based on the HLA typing data.


  • Lower risk of transfusion reactions and refractoriness, as the risk of antigen-antibody interaction is minimized.
  • Can be highly effective in patients with known HLA antibodies, as the transfused platelets are less likely to be targeted for destruction.


  • Finding a close HLA match can be time-consuming and may not always be possible, especially in ethnically diverse populations.
  • More expensive due to the costs of HLA typing and the specialized handling and coordination required.

HLA Avoidance (also known as Antigen-Negative or HLA-Compatible Platelets)


In this approach, the aim is not necessarily to match all HLA antigens between donor and recipient but to avoid those specific HLA antigens against which the recipient has developed antibodies.


  • The recipient is tested for HLA antibodies to identify the specific antigens that should be avoided.
  • Platelet units from donors lacking these particular antigens are then selected for transfusion, even if they are not a complete HLA match.


  • Faster and often easier to implement than finding a perfect HLA match, as you only need to avoid specific antigens rather than match all of them.
  • May be more readily available and cost-effective as compared to HLA-matched platelets.


  • While the risk of reaction is reduced, it is not as low as with HLA-matched platelets.
  • May still result in alloimmunization against other HLA antigens not previously sensitized against, as it's not a complete match.


2. Platelet-specific Alloantibodies: 

Human Platelet Antigens (HPA) are specific glycoproteins found on the membrane of platelets. Unlike HLA antigens, which are ubiquitously found on all nucleated cells, HPAs are specific to platelets. They serve as the scaffold for the binding of platelets to other cells and elements within the blood and are crucial for platelet function.

Mechanism of Alloimmunization

When a patient receives platelets from a donor with different HPAs, the recipient’s immune system can recognize these antigens as foreign and mount an antibody-mediated response against them. Like with HLA alloimmunization, the production of these antibodies is a learned response that sensitizes the immune system against future exposures to the same or similar HPAs.


Once alloimmunized against a specific HPA, any subsequent transfusion containing platelets expressing this HPA will be targeted by the recipient's immune system. The result is rapid clearance of these transfused platelets, leading to inadequate increases in platelet count and a persistent risk of bleeding complications.

Diagnostic Strategies

HPA Antibody Screening: Similar to HLA antibody screening, this involves testing the patient’s serum for antibodies against specific HPAs. Techniques such as enzyme-linked immunosorbent assays (ELISAs) can be used for this purpose.

Platelet Crossmatching: This involves incubating donor platelets with the recipient's serum to check for compatibility, although this is more commonly done for HLA rather than HPA matching.

Management Options

HPA-Matched Platelets: These are platelets from a donor with matching or compatible HPAs to those of the recipient. Such matches are typically rarer than HLA-matches but can be highly effective in preventing refractoriness.

Immunosuppression: In extreme cases, immunosuppressive therapies may be considered to reduce antibody levels temporarily, but this comes with its own set of risks, including increased susceptibility to infections.

Challenges in Clinical Practice

Limited Awareness and Testing: HPA alloimmunization is not as well-known or as routinely tested for as HLA alloimmunization, which can result in underdiagnosis.

Donor Pool: Finding HPA-matched donors is often even more difficult than finding HLA-matched donors, particularly because routine platelet donors are not typically typed for HPAs.

Economic Considerations: Specialized tests for HPA antibodies and HPA-matched platelets can be costly and may not be available in all healthcare settings.


Non-Immune Platelet Refractory Causes

Fever and Sepsis

Mechanism: Elevated body temperature and systemic infections can lead to increased platelet consumption and turnover. In sepsis, there's often disseminated activation of the clotting cascade, which consumes platelets faster than usual.

Clinical Implication: A patient with fever or sepsis may have a lower post-transfusion platelet count increment, not because the transfused platelets are being destroyed by antibodies, but because they're being used up rapidly.


Amphotericin B: An antifungal medication known to cause various side effects, including platelet aggregation, which might reduce the efficacy of platelet transfusion.

Heparin: An anticoagulant that can, in rare instances like heparin-induced thrombocytopenia (HIT), lead to platelet destruction.

Clinical Implication: Recognizing drug-induced thrombocytopenia is crucial, as the cessation of the offending drug can often reverse the platelet count decline.

DIC (Disseminated Intravascular Coagulation)

Mechanism: DIC is a disorder characterized by systemic activation of the blood clotting system. This leads to widespread formation of micro-clots in small blood vessels. As a result, platelets (and clotting factors) are consumed at an accelerated rate.

Clinical Implication: Patients with DIC may show poor increments in platelet counts after transfusion because of the rapid consumption of both endogenous and transfused platelets.


Mechanism: An enlarged spleen (splenomegaly) can sequester a larger portion of platelets than usual, reducing their circulating numbers.

Clinical Implication: Even after platelet transfusion, patients with significant splenomegaly might show suboptimal platelet count increments.

Graft-Versus-Host Disease (GVHD)

Mechanism: GVHD is a condition that can occur after stem cell or bone marrow transplantation, where donor cells attack the recipient's body. In the context of platelets, GVHD can contribute to bone marrow suppression, thus affecting platelet production.

Clinical Implication: Platelet refractoriness in GVHD isn't just about platelet destruction; it's also about reduced production. Addressing the underlying GVHD is crucial.


Mechanism: Active bleeding, especially in large amounts, can quickly consume the existing and transfused platelets.

Clinical Implication: In a bleeding patient, poor post-transfusion platelet count increments might be due to the immediate consumption of platelets at bleeding sites.


Clinical Evaluation and Diagnosis

The cornerstone of diagnosis is the calculated Corrected Count Increment (CCI) post-transfusion. A CCI lower than expected suggests refractoriness. Additional steps:

  • Blood Sample Analysis: To evaluate for alloantibodies against HLA and/or platelet-specific antigens.

  • Clinical Assessment: To rule out non-immune causes, like splenomegaly or sepsis.


Platelet Refractory Management Strategies

 Immune Mediated:

  • HLA-Matched Platelets: Ideally from closely HLA-matched donors or family members.

  • Cross-matched Platelets: Selected based on the absence of the specific antigens against which the patient has antibodies.

  • Desensitization: Rarely used, this involves administering the triggering antigen in increasing doses to reduce the recipient's antibody response.

Non-Immune Mediated:

Address the underlying cause, be it infection, medication, or other conditions.


Platelet Refractoriness Prevention

Leukoreduction: Removing white blood cells from transfused blood products reduces the risk of alloimmunization.

Antigen Matching: For at-risk patients, consider HLA-matched or cross-matched platelets.

Hemovigilance: For at-risk patients, transfuse platelets only when clinically indicated. If patient is not bleeding or at risk of bleeding, consider whether holding off on transfusion is possible.


Future Directions and Innovations:

  • Genomic Matching: Advanced molecular techniques offer potential for better donor-recipient matching.

  • Platelet Growth Factors: Agents like thrombopoietin mimetics can stimulate platelet production, potentially reducing the need for transfusions.

  • Therapeutic Modalities: Immunomodulation or extracorporeal treatments, like plasmapheresis, may play roles in specific refractory cases.

Weak D and Partial D

The D antigen, a significant component of the Rh blood group system, plays a crucial role in transfusion medicine. While most individuals are categorized as either RhD-positive (presence of the D antigen) or RhD-negative (absence of the D antigen), there are more intricate phenotypes to consider: weak D and partial D. Understanding these nuanced categories is vital for ensuring safe blood transfusions and managing pregnancies. 

DNA -- check for Weak or Partial D!

Molecular genotyping is vital for Weak D and Partial D typing because of its precision and the clinical implications of accurate identification. The process involves extracting DNA, amplifying specific regions of the RHD gene, and then analyzing or sequencing these regions to determine the exact variant.

Molecular Basis and Phenotypic Differences

  • Weak D: Weak D is characterized by a reduced expression of normal D antigens on the red blood cell (RBC) surface. This could result from genetic mutations leading to changes in the RhD protein's structure, affecting its external display on the RBC. Traditional serologic testing might classify these individuals as D-negative, but more sensitive tests will detect the D antigen's presence.

  • Partial D: Unlike weak D, which is about the decreased expression of normal D antigens, partial D results from structural variations of the D antigen. Individuals with partial D express all the epitopes of the D antigen, but one or more are altered. This alteration might cause them to produce anti-D antibodies if exposed to normal D antigen, posing a transfusion risk.

Clinical Implications in Transfusion Medicine

  • Blood Transfusions: People with weak D are typically safe to receive D-positive blood without the risk of alloimmunization, as their body recognizes the D antigen, albeit in lower amounts. However, for individuals with partial D, there's a potential risk when receiving D-positive blood since they might produce anti-D antibodies against the epitopes they lack.

  • Pregnancy and Hemolytic Disease of the Newborn (HDN): RhD incompatibility between a mother and her fetus can lead to HDN. Typically, RhD-negative mothers are at risk of developing anti-D antibodies when carrying an RhD-positive fetus. For mothers with weak D phenotypes, the risk of alloimmunization is minimal. However, for partial D mothers, the situation is complex. Depending on the specific epitopes they lack, they may still be at risk for developing anti-D antibodies.

Diagnostic Challenges and Recommendations

Detecting weak and partial D phenotypes requires advanced serological testing. Standard agglutination tests might miss weak D expressions, leading to incorrect classifications. Molecular genotyping can provide a more precise identification of weak D and partial D phenotypes.

For transfusion purposes, it might be simpler and more conservative to consider individuals with weak or partial D as D-negative, especially if detailed phenotypic or genotypic analysis isn't feasible. However, this approach can lead to unnecessary administration of Rh immunoglobulin (RhIg) in pregnancy and limit the availability of D-negative blood, which is rarer and more precious.

Strategies for Management

  • Blood Transfusions: To prevent alloimmunization, individuals with partial D phenotypes should ideally receive D-negative blood. In emergencies, when D-negative blood isn't available, RhIg can be administered as a preventive measure.

  • Pregnancy: All pregnant women should undergo RhD typing. For those with weak D phenotypes, RhIg prophylaxis might not be necessary. However, those with partial D phenotypes should be managed as RhD-negative, with RhIg administration to prevent potential alloimmunization. 

    Weak D Types:

    The term "Weak D" is used to describe red blood cells (RBCs) that exhibit a weakened expression of the D antigen but produce all epitopes of the RhD antigen. Over 150 Weak D types have been described, but the common ones are:

    1. Weak D Type 1, 2, and 3: These are the most frequent types in Caucasians. From a clinical standpoint, individuals with these types are not at risk for D alloimmunization, even upon exposure to D-positive blood.

    2. Weak D Type 4: This group consists of multiple subtypes (e.g., Type 4.0, 4.1, 4.2, etc.). Some subtypes can produce an anti-D response when exposed to D-positive RBCs, especially the Type 4.2 variant. RhIg prophylaxis is often indicated in this case.

    3. Other Weak D Types: Many other types exist, with varying clinical significance. Their potential to produce an anti-D response upon exposure to D-positive RBCs varies.

    Partial D Variants:

    Partial D phenotypes arise due to genetic mutations leading to the production of an altered D antigen. The clinical risk associated with Partial D phenotypes pertains mainly to potential alloimmunization upon exposure to regular D-positive RBCs.


    DIIIa, DIIIb, and DIIIc

    DVa and DVb 

    D^U (or DAU): A complex category, which includes numerous subtypes like DAU-0, DAU-1, DAU-2, etc. Their clinical relevance varies, but some DAU types can result in alloimmunization upon exposure to standard D-positive blood.

     DVI - The DVI variant represents an epitopic modification within the D antigen complex, resulting in the absence of certain epitopes that are present in a regular D antigen. DVI arises due to the presence of specific alleles of the RHD gene. The molecular characterization of DVI shows hybrid RHD-CE-D gene structures.

    And many more!!


    1. Weak D: Most guidelines now suggest that individuals with Weak D Type 1, 2, or 3 can safely receive D-positive blood without the risk of alloimmunization. For other Weak D types, the decision should be made on a case-by-case basis, considering potential risks.

    2. Partial D: Due to the risk of alloimmunization, individuals with known Partial D phenotypes should receive D-negative blood, especially when the specific subtype's risk is not well-defined.

    3. Pregnancy: Women with Weak D types not associated with alloimmunization (e.g., Type 1, 2, 3) do not typically require RhIg prophylaxis. However, those with certain Partial D phenotypes or uncharacterized Weak D types may benefit from a more conservative approach, including RhIg administration and closer monitoring.

Subgroups of (Blood Type) B?

This post brought to you by...the Letter B!
Yes, they do exist! We are generally much more familiar with subgroups of A, especially in patients who have made an Anti-A1, but subgroups of B do exist in patient populations. They are rare, but this lack of prevalence can likely be partially explained by Blood group B having a much lower prevalence than A to begin with. 

Here's a breakdown of the B subgroups:

B3 Subgroup

Antigenic Expression:
  • The B3 subgroup presents with a weaker expression of the B antigen when compared to the regular B blood group. This diminished strength is often the result of changes in the sugar structures that form the basis of the B antigen.
Mixed-Field Agglutination:
  • B3 cells often display a phenomenon called mixed-field agglutination when tested with anti-B serums. Mixed-field agglutination refers to the simultaneous presence of agglutinated and non-agglutinated red cells in the same sample. This can occur if only a fraction of the RBCs in the sample express the B antigen, leading to partial clumping.
Genetic Inheritance:
  • The B3 phenotype appears to have an autosomal dominant pattern of inheritance. It's inherited in families, and if one parent carries the gene, there's a 50% chance that their offspring will also express this subgroup.
Differentiation from Acquired B Antigen:
  • Acquired B antigen often arises due to external factors, typically associated with diseases affecting the gastrointestinal tract. The enzymes produced by certain bacteria can modify the A antigen to resemble B antigen, leading to the "acquired B" phenotype.
  • Differentiating between B3 and acquired B is essential for several reasons:
    • Transfusion Reactions: Patients with acquired B can experience transfusion reactions if given blood from true B or AB donors. Knowing the difference helps guide appropriate blood product selection.
    • Organ Transplantation: Similar to transfusions, ensuring the correct blood type and its nuances are critical for organ transplants.
    • Diagnostic Significance: Acquired B antigen can be an indicator of an underlying disease. Recognizing this can be a diagnostic clue, especially in patients with unexplained anemia or those who have a history suggestive of gastrointestinal disease.

Further Considerations:

  1. Testing: Enhanced testing methodologies, including the use of different antisera or molecular techniques, may help clarify ambiguous results.
  2. Clinical Implications: While B3 is primarily of academic interest, its recognition can prevent potential transfusion-related complications. Blood bank specialists must be aware of its existence and its differentiation from the more clinically significant acquired B phenotype.

In summary, the B3 subgroup, while rare, represents a fascinating intersection of genetics, biochemistry, and clinical medicine within the realm of immunohematology.

Bx (Bend) Subgroup

Antigenic Expression:
  • The Bx subgroup, similar to B3, displays a weaker expression of the B antigen on the surface of red blood cells. However, what distinguishes Bx (Bend) cells from typical B cells is their unique reactivity pattern.
Reactivity with Anti-B:
  • The Bx cells demonstrate weak agglutination (clumping) when reacted with anti-B sera. This weak agglutination can sometimes be misinterpreted, leading to potential misclassification of the blood type, especially if other subgroups or acquired conditions aren't considered.
Temperature-Dependent Reactivity:
  • One of the defining features of the Bx (Bend) subgroup is its enhanced reactivity at colder temperatures, typically around 4°C. When Bx cells are tested at this lower temperature, the agglutination reaction with anti-B sera is stronger.
  • The temperature-dependent reactivity suggests specific structural or conformational changes in the B antigen that favor binding to the anti-B antibody at lower temperatures.
Clinical Implications:
  • Blood Transfusion: Recognizing the Bx (Bend) subgroup is critical for blood banks, as misclassification can lead to transfusion reactions. If a person with the Bx phenotype is mistyped as group O and then receives B or AB blood, it could cause a reaction.
  • Laboratory Practices: Because of its temperature-dependent reactivity, blood banks must be vigilant when performing tests, especially if the reactions are carried out at different temperatures. Moreover, if a blood bank specialist encounters unexpected weak B reactions, the Bx (Bend) subgroup should be considered, and additional tests at various temperatures may be conducted.
  • Genetics and Biochemistry: While the Bx (Bend) subgroup has been defined serologically, the genetic and biochemical underpinnings are not as well-understood as the main blood group types. There may be genetic mutations or alterations in the enzymes involved in synthesizing the B antigen, leading to the distinct Bx phenotype.

Bm (B modified) Subgroup

Antigenic Expression:

  • The Bm subgroup carries a modified or variant form of the B antigen on the surface of red blood cells. This modification leads to a differential reactivity when exposed to certain anti-B reagents.

Reactivity with Anti-B:

  • Bm cells typically show weaker reactions or sometimes even negative reactions with specific monoclonal anti-B reagents. This can create confusion in blood typing, potentially leading to misclassification.
  • The reactivity pattern varies depending on the origin of the anti-B reagent used, especially between monoclonal and polyclonal sources. Polyclonal anti-B sera, derived from multiple immune cells, might still show agglutination with Bm cells, while certain monoclonal reagents, originating from a single immune cell clone, might not.

Geographical and Ethnic Distribution:

  • The Bm phenotype has been found in various populations worldwide but remains relatively rare. Its presence in both African and Caucasian populations suggests that it's not limited to a specific ethnic group, though its prevalence might vary across different communities.
  • Genetics and Biochemistry: The specific genetic and biochemical basis for the Bm phenotype is not entirely clear. However, it is believed to arise from genetic mutations or alterations in the enzymes responsible for B antigen synthesis, leading to a modified structure.

Bel Subgroup

Antigenic Expression:

  • Individuals with the Bel subgroup have red blood cells that express an extremely low amount of the B antigen—so low that it's nearly indistinguishable from an O blood type using conventional serological methods.
  • Because of this minute expression, routine ABO typing may detect these cells as type O, leading to potential misclassification.

Anti-B Production:

  • Despite the almost non-existent B antigen expression, individuals with the Bel phenotype can produce anti-B antibodies. The production of this antibody suggests that the level of B antigen present on their cells is insufficient to induce tolerance.
  • The anti-B produced by Bel individuals is not benign. If a Bel individual receives blood from a B or AB donor, this anti-B can target and destroy the transfused red blood cells, leading to a hemolytic transfusion reaction—a serious and potentially life-threatening adverse event.

Clinical Implications:

  • Blood Transfusion: Given the potential for Bel individuals to produce anti-B, it's paramount to identify this subgroup accurately. Misidentification could lead to providing B or AB blood to a Bel recipient, which would trigger a hemolytic reaction.
  • Laboratory Challenges: The primary challenge is the potential misclassification of Bel as O due to the almost non-existent B antigen expression. Advanced serological methods, such as adsorption and elution techniques, or molecular tests may be required to detect and confirm the presence of the Bel phenotype.
  • Pregnancy and Hemolytic Disease of the Newborn (HDN): While the focus is often on transfusion, it's also essential to consider potential complications in pregnancy. If a Bel mother is pregnant with a fetus expressing the B antigen, there's a risk, albeit low, for HDN.

Historical Context:

  • The name "Bel" is derived from the initial patient's name in whom this phenotype was first identified. Over time, as with many blood group anomalies, the name has been used to represent the entire subgroup.

Acquired B Blood Group Phenotype

Nature of Change:

  • As the name suggests, this alteration in blood group is not inherited. Instead, it arises due to external factors during an individual's lifetime.
  • The phenomenon involves a modification of the A antigen on the red cell surface, causing it to mimic the B antigen.


  • The transformation of the A antigen to resemble the B antigen is primarily attributed to the action of bacterial enzymes. Certain bacteria, especially those flourishing in gastrointestinal conditions, produce enzymes known as deacetylases.
  • These microbial deacetylase enzymes remove acetyl groups from the A antigen, altering its structure. The modified A antigen then mimics the B antigen in serological reactions.

Clinical Implications:

  • Blood Typing Discrepancies: The most immediate consequence of the Acquired B phenomenon is a discrepancy in blood typing. An individual previously typed as group A may appear as group AB due to the presence of the modified A antigen that reacts with anti-B sera.
  • Transfusion Concerns: Given the altered blood typing results, there's a potential risk of transfusion errors. However, it's important to note that the acquired B antigen typically does not trigger an immune response. Thus, even if group B blood was transfused into a patient with Acquired B, hemolytic reactions are unlikely. Still, it's crucial to adhere to blood transfusion guidelines and provide group-specific or type O blood when in doubt.

Associated Conditions:

  • Acquired B is most frequently associated with gastrointestinal diseases, where the growth and activity of certain bacteria are enhanced. Common conditions include:
    • Colon cancer
    • Intestinal obstruction
    • Peptic ulcers
    • Other gastrointestinal malignancies
  • The association with gastrointestinal diseases, especially colon cancer, implies that the presence of Acquired B could serve as a diagnostic hint, suggesting the need for further gastrointestinal evaluation.

Resolution and Diagnosis:

  • Acquired B is generally a transient phenomenon. Once the underlying gastrointestinal condition is addressed or if the microbial flora is altered (e.g., due to antibiotics), the blood group typically reverts to its original type.
  • If Acquired B is suspected, repeating the blood group test after treating the individual with acid or enzymes can revert the modified A antigen back to its original state, thus confirming the diagnosis.

Differentiation from Genuine AB:

  • In order to differentiate Acquired B from a true AB blood type, a detailed patient history is crucial. Salivary blood grouping, which remains unaffected by the acquired B phenomenon, can also aid in distinguishing between the two.

In essence, Acquired B serves as a testament to the dynamic nature of the human body and its interactions with the microbial environment. Recognizing such anomalies and understanding their underlying mechanisms ensures patient safety and can also provide valuable diagnostic insights.

B(A) Subgroup of Blood Group B

Nature and Origin:

  • The B(A) phenotype exhibits characteristics of both B and A antigens on the red cell surface, but the A-like properties are weaker than those seen in a true A antigen.
  • The origin of the A-like quality in these B cells isn't entirely clear. It's believed that this phenotype arises due to the activity of an A transferase enzyme that is functioning at a reduced capacity. This enzyme adds specific sugars to the H antigen, turning it into an A antigen. However, in the case of B(A) subgroup, this enzyme's activity isn't as efficient as in regular A blood group individuals, leading to a weaker A expression.

Serological Characteristics:

  • Blood samples from individuals with B(A) typically react with anti-B and anti-A sera, but the reaction with anti-A is weaker. This can cause discrepancies in blood grouping.
  • Monoclonal anti-A reagents might not detect the weaker A antigen, but polyclonal anti-A reagents (which are generally more sensitive) may produce a reaction.

Clinical Implications:

  • Blood Typing Confusion: The most significant concern with B(A) is the potential for misclassification. If not detected and classified correctly, a B(A) individual could be mistyped as AB or B.
  • Transfusion Issues: A person with a B(A) phenotype can produce anti-A antibodies, even though they have A-like properties on their cells. This means they can potentially have a transfusion reaction if given blood from a true A or AB donor.


  • Thorough serological tests, often employing a series of anti-A reagents and adsorption-elution techniques, can help in correctly identifying this subgroup. Adsorption techniques can remove the interfering antibodies, and elution can then be used to identify the eluted antibodies.
  • A detailed patient history is also beneficial. Some B(A) phenotypes are acquired due to underlying conditions, similar to the Acquired B phenomenon.


  • The prevalence of the B(A) subgroup varies among populations but is generally rare.
  • Some studies suggest a higher occurrence in certain Asian populations, though it's still a rare phenomenon.

Donath-Landsteiner Antibodies

For many, the intricacies of the human immune system remain an enigma, especially when it comes to rare autoimmune conditions. Today, we are diving deep into one such mysterious condition: Paroxysmal Cold Hemoglobinuria (PCH), and the unique antibody associated with it - the Donath-Landsteiner (D-L) antibody.

The Enigma of PCH and its Association with D-L Antibodies

Paroxysmal Cold Hemoglobinuria, or PCH, is an unusual autoimmune hemolytic anemia. In simpler terms, it's where the body's defense system, mistakenly, targets and destroys its own red blood cells (RBCs). What sets PCH apart from other anemias is its trigger: cold temperatures.

While PCH can strike any age group, children and young adults are particularly vulnerable. Historically linked to syphilis in adults, PCH today is more commonly seen following viral infections in children. This condition is typically transient in nature but can cause significant acute symptoms.

Donath-Landsteiner hemolytic anemia has been correlated with various viral infections, including:

  • The Epstein-Barr virus (commonly known as EBV).
  • Coxsackievirus type A9.
  • Adenovirus.
  • The Cytomegalovirus, abbreviated as CMV.
  • Parvovirus.
  • Varicella zoster virus, the causative agent of chickenpox.
  • Mumps.
  • Measles.

The main culprit behind this self-destructive process is the Donath-Landsteiner antibody. What's fascinating about this antibody is its specificity. Unlike other autoantibodies, D-L antibodies specifically target a carbohydrate antigen called the P antigen found on the surface of RBCs.

The Cold Activation Mechanism

D-L antibodies stand out in the realm of immunology due to their distinctive behavior. Unlike the typical IgM antibodies, which commonly react at cold temperatures, D-L antibodies are predominantly of the IgG class. Yet, they share the unique characteristic of reacting at cold temperatures, much like their IgM counterparts. This dual peculiarity—being an IgG that reacts to cold—makes them particularly notable in the field of blood bank and transfusion medicine.

D-L antibodies are uniquely temperature-sensitive. During exposure to cold, these antibodies bind to the P antigen on RBCs. As the blood rewarm, typically when it circulates back to the core of the body, the complement system - a component of the immune system - gets activated. This activation results in the destruction (hemolysis) of RBCs.

Symptoms can vary from mild fatigue to severe anemia, with dark or red urine indicating the presence of hemoglobin from the lysed RBCs. This condition can be alarming, especially if there's an extensive destruction of RBCs, leading to acute anemia.

The Diagnostic Challenge

Diagnosing PCH requires a high degree of clinical suspicion. The connection between cold exposure and the onset of symptoms is crucial for diagnosis. Standard blood tests may reveal anemia and evidence of hemolysis, such as elevated bilirubin, low haptoglobin, and increased lactate dehydrogenase (LDH).

However, the definitive diagnostic test is the Donath-Landsteiner test. This test exposes the patient's blood to cold temperatures, then warms it to body temperature to see if hemolysis occurs in the presence of complement. A positive test will confirm the presence of D-L antibodies and the diagnosis of PCH.

Treatment Strategies

Managing PCH revolves around avoiding triggers and treating acute episodes. Since cold exposure is a primary trigger, patients are often counseled to avoid cold environments and ensure their extremities are well-protected during chilly days.

Treatment during acute hemolytic episodes may involve blood transfusions to replenish the RBCs lost to hemolysis. Immunosuppressive medications like corticosteroids can also be used to temper the immune response. In rare, persistent cases, stronger immunosuppressive drugs or even a bone marrow transplant might be considered.

The Super Coombs


The Super Coombs to the rescue!

When the regular Coombs doesn't cut it, reach for the Super Coombs!

What is a Super Coombs?

It's a silly term (that may sometimes be clinically used) for the testing performed for "DAT negative autoimmune hemolytic anemia" investigation. A physician may request this workup when traditional methods of performing the Direct Coombs (or Direct Antiglobulin Test) turn up negative, but the patient is still exhibiting signs of Hemolytic Anemia and cannot be explained by other reasons. Typically these patients may have lower hemoglobin and hematocrit and see inappropriate responses to transfusion, have an extremely low or undetectable Haptoglobin, elevated LDH and bilirubin, etc. 

As we may know, negative doesn't always mean "Definitely not there". Negative simply means below the detectable limits of the testing system. In many cases, negative does mean "not there" and we can otherwise trust the testing system, but sometimes analytes exist in such small quantities that normal testing systems may not exhibit positive reactivity. This is true for patients with "DAT negative autoimmune hemolytic anemia". As such, a negative routinely performed DAT does not technically rule out AIHA.

But What Entails A Super Coombs? You Still Didn't Say.

 A Super Coombs, Enhanced DAT, or DAT Negative AIHA workup is actually a battery of tests performed on a patient sample to detect Red Blood Cell bound antibodies or complement (IgG/C3) on the cell surface that may be missed by traditional DAT testing. More often than not, this testing is performed at an Immunohematology Reference lab and is NOT performed at routine hospital Blood Bank laboratory. Physicians interested in this testing should expect a several day turn-around-time due to the need to ship out the patient's specimens to an outside lab. 

There are no rigid guidelines on how to perform, or WHAT to perform for a DAT negative AIHA workup, but several tests do exist to try and coax out some reactivity. Indeed, many scientists believe the number one reason for DAT negative AIHA is simply RBC-bound IgG antibody being below the threshold of detectability in a normal Some tests look for weak / low affinity reactivities, others look for possible non IgG causes such as IgM or IgA bound antibodies.


PolybreneThe Direct Polybrene Test is a rapid method, but its efficacy hinges on the technician's expertise. Polybrene, scientifically known as hexadimethrine bromide, causes a general aggregation of healthy RBCs, facilitating the cross-linking of antibody molecules. It's a fascinating phenomenon: after introducing sodium citrate solution, general aggregates disperse, but any antibody-driven agglutination remains, undeterred by the neutralization of the Polybrene effect.

Should antibodies remain undetected post-dispersion, the test can segue into an antiglobulin procedure, specifically targeting anti-IgG. Prior research has illuminated the Direct Polybrene Test's prowess: its sensitivity is nearly on par with flow cytometry and equals the ELAT in detecting minuscule concentrations of RBC-associated IgG. The test has also proven invaluable for samples exhibiting DAT-negative AIHA.

Let's delve into Polybrene's mechanics. By counterbalancing the negative charge gracing the RBC surface, Polybrene optimizes antibody adherence. This action is instrumental when striving to pinpoint antibodies that exist in trace amounts or are traditionally elusive.

Blood bank specialists might appreciate this efficient manual Polybrene procedure for discerning RBC antibodies, tailored for routine laboratory apparatus:

  • Combine RBCs with test sera in a low-ionic medium, keeping them at room temperature for approximately one minute.

  • Introduce Polybrene, an integral quaternary ammonium polymer, prompting RBCs to aggregate nonspecifically.

  • Following centrifugation, decant the cell-free supernatant.

  • Neutralize the Polybrene-induced effect on the cells using a sodium citrate-glucose solution, and subsequently, assess the hemagglutination outcomes both macroscopically and under a microscope.

Remarkably, this entire protocol can be executed in a mere three minutes. Within the Rh system, its sensitivity surpasses the antiglobulin reaction by significant folds. Most antigenic systems, save for Kell, exhibit this heightened sensitivity. Nonetheless, Kell system sensitivity can be augmented significantly via a supplemental antiglobulin reaction (on the sensitized polybrene processed cells), provided the utilized antiglobulin reagent is devoid of anti-C4 and anti-C3 activities. For those aiming to boost the test's sensitivity to cold-reactive antibodies, a brief pre-treatment chill (about 30 seconds) before introducing the citrate-glucose solution is recommended.

Summary -- Polybrene induces aggregation of RBCs. Aggregation is dispersed by sodium citrate. However, if RBC bound antibody is present, RBCs will NOT disperse, thus the test would then be positive for RBC bound antibody below the detectable limit of routine testing.

4°C LISS Wash

Cold LISS wash!
Chill out!
The 4°C LISS wash is a specialized technique developed to heighten the sensitivity of the DAT, especially when the standard DAT might not pick up on lower levels of bound antibodies or complement proteins.

Washing RBCs with a cold LISS can slow down the dissociation of some antibodies from the RBCs, which could otherwise be missed at room temperature.

So, Why is This Relevant to DAT-negative AIHA?

In some AIHA cases, the antibodies bound to RBCs might be in very low quantities or might dissociate easily from the RBC surface. The standard DAT could miss these antibodies, resulting in a false-negative result. By using the 4°C LISS wash, we can amplify the chances of detecting these otherwise elusive antibodies, ensuring that cases of AIHA don't go undetected.

Micro-Column Agglutination 

Micro-Column agglutination, commonly referred to as "gel testing," is a technique in immunohematology that harnesses microtubes filled with a specialized gel (usually dextran-acrylamide) to detect interactions between red blood cells (RBCs) and antibodies. The gel acts as a physical barrier, sorting RBCs based on whether they've agglutinated (clumped together) due to the presence of bound antibodies.

How Does It Differ from Traditional Methods?

Traditional testing often involves looking for visible clumping of RBCs in liquid. In contrast, column agglutination uses the gel's properties to enhance the visibility and clarity of agglutination. If RBCs are bound together by antibodies, they'll form a line or clump within the gel, while unbound RBCs will travel to the bottom of the column during centrifugation. This gives a clear visual indicator of the presence of antibodies.

Column Agglutination's Role in DAT-negative AIHA:

AIHA (Autoimmune Hemolytic Anemia) is characterized by the body's immune system mistakenly targeting its RBCs. The Direct Antiglobulin Test (DAT) is a primary tool to diagnose this by detecting antibodies bound to RBCs. However, sometimes AIHA can be elusive, presenting as DAT-negative.

In such cases, the heightened sensitivity of column agglutination becomes invaluable. Here's why:

  • Enhanced Detection: The gel matrix can trap even weakly agglutinated RBCs, making it more likely to spot cases where antibody binding is minimal.

  • Clear Results: By physically separating clumped and non-clumped cells, the gel method provides a stark visual distinction, reducing interpretative ambiguities.

  • Reduced False Positives: Gel testing minimizes the effects of rouleaux (a phenomenon where RBCs stack like coins, sometimes mimicking genuine agglutination).

In Essence:

Column agglutination provides a refined lens for spotting antibody-RBC interactions, especially when traditional methods like the DAT fall short. For cases of suspected AIHA where the DAT is negative, this method acts as a powerful secondary tool, ensuring that even subtle cases don't escape notice.

Flow Cytometry 

How Does Flow Cytometry Work in AIHA Context?

  1. Labeling Cells: In the context of AIHA, RBCs are often labeled with fluorescently-tagged antibodies that specifically bind to human antibodies or complement proteins on the RBC surface.

  2. Analysis: Once labeled, the RBCs are passed through the flow cytometer. When these fluorescently-tagged RBCs pass through the laser beam, they emit light, which is detected and analyzed.

  3. Data Interpretation: The resulting data is then displayed in histograms or scatter plots, showing the presence or absence (and often the amount) of antibodies or complement on the surface of RBCs.

Why Use Flow Cytometry for DAT-negative AIHA?

The Direct Antiglobulin Test (DAT) is a cornerstone in diagnosing AIHA, as it detects antibodies or complement proteins bound to RBCs. However, not all AIHA cases show a positive DAT, even when the condition is present.

Flow cytometry comes into play in such challenging cases for several reasons:

  • Increased Sensitivity: Flow cytometry can detect even small amounts of antibodies or complement on RBCs, making it particularly valuable for cases with low-level binding that might be missed by traditional methods.

  • Quantitative Analysis: Besides just identifying the presence of antibodies, flow cytometry can give a quantitative assessment, indicating the density of antibody binding on RBCs.

  • Comprehensive Profiling: With the capability to use multiple fluorescent tags, flow cytometry can help discern the specific types of antibodies or complement proteins present, offering a more detailed profile of the immune response.

In a study, Flow Cytometry detected more AIHA cases than the Gel Card Test, reaffirming its sensitivity. Several reasons, including the low level of sensitizing red cell autoantibody or the involvement of low-affinity antibodies, can result in false negatives with traditional testing methods.

Anti-IgA and Anti-IgM

Routine DAT testing involves the use of Anti-IgG. However, some cases of AIHA may involve Anti-IgA or Anti-IgM, thus appearing negative through the use of Anti-IgG DAT testing. 

BioRad Gel Testing card with IgA and IgM included!
BioRad Gel Testing card with IgA and IgM included!

  • IgA-mediated AIHA is rare compared to its IgG counterpart.
  • In these instances, IgA autoantibodies target antigens on the red blood cell surface. The subsequent immune response leads to red cell destruction.


  • IgM is a large pentameric molecule. When IgM autoantibodies bind to red blood cells, they can sometimes trigger the classical complement pathway leading to hemolysis.
  • At colder temperatures, IgM can be particularly effective at binding to red cells, leading to cold agglutinin disease (CAD), a subset of AIHA. In these cases, the hemolysis is often exacerbated by cold exposure.
  • Again, standard DAT may not always detect IgM, and specialized reagents would be needed.
Have you performed a DAT negative AIHA workup? Let us know!

Anti-U. Should U Worry About It?

What is Anti-U?
U! What's better than U?

Anti-U is a blood group antigen that has gained attention for its importance in blood transfusions and potential complications during pregnancy. Discovered in 1961, Anti-U is part of the MNS blood group system and is relatively rare in the general population. The presence of this antigen can impact the blood transfusion process, particularly for pregnant women of African descent. In this post, we will explore the significance of Anti-U, its association with genotype, phenotype, and race, and the unique challenges faced by pregnant women with this blood group.

Anti-U antibody is an antibody that targets the U antigen, which is part of the MNS blood group system. The MNS system is one of the most complex blood group systems, with over 40 different antigens that can cause an immune response if they are not properly matched during a blood transfusion.

Anti-U and Race

The prevalence of the Anti-U antigen varies across different populations. It is almost entirely absent in individuals of African descent, with only 1-2% of the African population having the U antigen. In contrast, the U antigen is present in approximately 99.8% of people of European origin. Consequently, the incidence of Anti-U antibodies is higher among individuals of African descent, making it an important consideration for blood transfusions and pregnancies within this demographic.

Challenges for Pregnant Women

For pregnant women with Anti-U antibodies, there is an increased risk of hemolytic disease of the fetus and newborn (HDFN). This condition occurs when maternal antibodies cross the placenta and attack the red blood cells of the developing fetus, causing anemia and potentially leading to fetal death or severe neonatal complications. 

Mothers who are identified as having anti-U antibody may require specialized care to prevent HDN. The mother's blood will be screened for the presence of the antibody, and if it is found, she will need regular monitoring of her pregnancy to ensure that the fetus is not affected. This may involve frequent ultrasounds and monitoring of the fetus's blood counts.

If a mother with anti-U antibody gives birth to a baby with the U antigen, the baby may develop HDN, which can cause anemia, jaundice, and other complications. To prevent this, the baby's antigen and antibody status will be checked at birth, and if necessary, the baby may require a blood transfusion with SsU negative blood to prevent HDN.


U- patients are always S- and s-. This S-s-U negative phenotype is due to the patient lacking glycophorin B, which is the RBC glycoprotein responsible for S and s antigen expression. However, not all S-s- patients will be U negative. There exists a variant of the U antigen that produces seemingly incomplete epitopes of the antigen. Figure this similar to partial D patients. This is typically notated as S-s-U+var. Although the U antigen is present on the Red Cell, it has variable missing epitopes and patients can still create an Anti-U towards these missing epitopes were they to come in contact with U+ blood. 

 Acquiring U Negative Blood

In cases where a blood transfusion is necessary for someone with Anti-U antibodies, finding compatible blood can be challenging. The rarity of the antigen, especially among African populations, means that sourcing blood with the U antigen may be difficult. To address this issue, rare donor programs have been established to maintain frozen stocks of blood with the U antigen. These programs facilitate access to compatible blood for those in need, reducing the risk of transfusion reactions.

Many transfusion services will opt to have the unit typed for S and s as well as U, thus patients will often receive S-s-U- blood. Thankfully, as previously mentioned, if the unit is U negative, the unit very well should be S and s negative as well. It is not enough to search for S-s- units, as some may still be U+.

Identifying Anti-U

Care must be taken to properly identify an Anti-U especially in pregnant women., to ensure fetal health and safety. Many people working in a transfusion center Blood Bank may have never seen an Anti-U before, but that certainly depends on the size and population of the hospital. Those working in reference labs would obviously have a higher chance of seeing an Anti-U come through.  

Anti-U initially appears to look like a panagglutinin. Generally all screening cells will be U positive, thus all screening cells will be positive. Additionally, many panels do not have a U negative cell on them. This is lot dependent of course, some do. As such, many panels will also appear as a panagglutinin due to the lack of U negative cells. 

Unless you specifically knew to look for Anti-U, you'd probably be thinking Warm Autoantibody, Daratumumab interference, Anti-k? Who knows. Most people wouldn't think Anti-U. Most hospitals who didn't have a panel with a U negative cell on it would most likely end up sending the specimens to a reference lab for further workup and ID. 

Those lucky enough to have a U negative cell panel will then find it very difficult to rule everything else out, prompting the need for potential send out as well. This is where keeping old expired panels in the back fridge comes in handy. If you can QC a cell and it passes, you're good as gold to use it!

We recently had an Anti-U patient, and despite finding 4 U negative panel cells (current and expired), we still couldn't rule out Jkb,Fya,C,K,E. We had to work with the Red Cross to find S-s-U-Jkb-Fya-C-K-E- blood as we weren't immediately able to send the patient out for workup as they were an outpatient scheduled for OB surgery. They came through with some previously frozen deglycerolized RBCs! 

Storage Lesion

Another kind of storage lesion..
Now that's a office style storage lesion!
Blood transfusions have saved countless lives by replacing lost or deficient blood components, such as red blood cells (RBCs), platelets, and plasma. However, the quality and effectiveness of blood products can be affected by storage time, leading to a set of changes known as storage lesion. In this article, we'll explore what storage lesion is, how it affects blood products, and why fresher blood may be better for some people.

What is Storage Lesion in Blood Products?

Storage lesion refers to the changes that occur in blood products over time, particularly during refrigerated storage. These changes can affect the viability, function, and safety of the blood components, and may vary depending on the type of product and storage conditions. Some of the common changes associated with storage lesion in blood products include:

  • Reduced levels of adenosine triphosphate (ATP), which is essential for energy metabolism and cell membrane integrity;
  • Increased levels of reactive oxygen species (ROS), which can damage cell membranes, proteins, and DNA;
  • Loss of membrane flexibility and deformability, which can impair oxygen delivery and hemostasis;
  • Alterations in blood cell surface markers and activation status, which can affect immune responses and thrombosis;
  • Changes in coagulation factors, complement proteins, and cytokines, which can modulate inflammation and immune reactions.
  • Decreased pH: During storage, the pH of blood products can decrease, which can impair the function of enzymes and other proteins in the blood.

These changes can have important clinical implications for patients who receive transfusions, especially those who are critically ill, have underlying diseases, or require frequent transfusions. For example, storage lesion in RBCs can cause an increase in potassium levels and an increase in free hemoglobin, which can lead to hyperkalemia and hemolysis in susceptible patients. Moreover, storage lesion can compromise oxygen delivery, exacerbate inflammation, and increase the risk of transfusion-related complications, such as transfusion-associated circulatory overload (TACO), transfusion-related acute lung injury (TRALI), and transfusion-transmitted infections (TTIs).

Platelet Storage Lesion

During platelet storage, several biochemical and physiological changes can occur, collectively known as the platelet storage lesion. Some of the common changes associated with the platelet storage lesion include:

  • Loss of platelet function: Platelets stored for longer durations may become less effective at forming blood clots or adhering to damaged blood vessels.
  • Activation of platelets: Platelets can become activated during storage, leading to the release of proinflammatory and procoagulant substances, such as cytokines, thromboxane A2, and platelet factor 4.
  • Loss of platelet viability: Platelets can undergo apoptosis or programmed cell death during storage, leading to a reduced number of viable cells.
  • Changes in platelet membrane structure and composition: Platelets stored for longer durations may undergo structural changes in their membranes, such as increased lipid peroxidation, which can impair their function and survival.
  • Bacterial contamination: Platelet storage bags and units can become contaminated with bacteria, which can cause transfusion-related infections and other complications.

Why Fresher Blood May Be Better for Some People?

Given the potential adverse effects of storage lesion in blood products, researchers and clinicians have explored various strategies to minimize its impact. One of these strategies is to use fresher blood, i.e., blood that has been stored for a shorter duration. This approach is based on the hypothesis that fresher blood has fewer storage lesions and, therefore, may be more effective and safer for some patients.

Several studies have investigated the association between blood storage time and clinical outcomes in various patient populations. For example, a randomized controlled trial published in the New England Journal of Medicine in 2015 found that transfusion of fresher RBCs (stored for less than 10 days) did not improve mortality or morbidity in critically ill adults compared to standard-issue RBCs (stored for up to 42 days). However, the study also showed that fresher blood was associated with a lower risk of new-onset multiple organ failure, suggesting a potential benefit for specific subgroups of patients.

Another study published in JAMA in 2021 analyzed data from nearly 300,000 transfusions in more than 80,000 patients and found that fresher RBCs were associated with a lower risk of in-hospital mortality and complications, especially in patients with sepsis, acute respiratory distress syndrome (ARDS), and cardiac surgery. The study also reported that fresher RBCs had higher levels of ATP, lower levels of potassium, and less hemolysis than older RBCs, supporting the hypothesis that storage lesion contributes to the adverse effects of blood transfusions.

However, using fresher blood may not be feasible or cost-effective in all settings. Physicians should order and use judiciously, and transfusion centers should be sure to double check with the physician before proceeding.

RhIG to an Rh positive Patient? The Medical Splenectomy

 The nursing floor just requested RhIG on an Rh positive MALE? Why???

They likely want to perform a "medical splenectomy"!

Patients with ITP or idiopathic (or immune) thrombocytic purpura create an autoantibody towards antigens on platelets which subsequently marks the platelets for destruction and they are removed from circulation causing thrombocytopenia. Typically, physicians will try treatments such as steroids first, to dampen the immune systems response and see if platelet counts recover. If not, there are other options available. Very often physicians will spring for IVIg (Intravenous Immunoglobulin). The mechanism in which IVIg works in regards to platelets in ITP is not fully understood but it is postulated the immunoglobulins bind receptors on macrophages, leaving them unable to interact with platelets and target them for destruction. This inability to mark the platelets for destruction means more platelets remain in circulation. 

There is another option, however, and it is still considered a first-line therapy, much like IVIg is. RhIG! Yes, Rh immune globulin, the same stuff you've been giving Rh negative pregnant mothers all this time to prevent RhD alloimmunization. WinRho SDF and Rhophylac brands are approved for IV usage in ITP situations. RhoGAM (a specific brand of RhIG) is typically given only as an IM shot. RhoGAM can ultimately be used, but patients may need multiple shots, making WinRho and Rhophylac a better choice. 

To receive IV RhIG for ITP treatment, patients MUST be Rh positive, must still have a functional spleen, and should not be exhibiting signs of hemolytic anemia or DIC. Providing RhIG to Rh positive patients for treatment of ITP is known colloquially as performing a "medical splenectomy". This is because removing the spleen is a drastic measure to stop platelet sequestration and destruction, as it is where the platelets get sent for destruction once they are antibody targeted. In more medically scientific terms it is know as an Fc receptor blockade mechanism. 

This mechanism can be described as such:

The anti-D from the RhIG preparation attaches to the RhD positive red cells of the recipient. Essentially, the RhIG "opsonizes" the RhD red blood cells, targeting them for destruction. The RhD positive red cells are brought through the reticuloendothelial system via phagocytic cells like macrophages where they will be destroyed in the spleen. This massive increase in antibody marked cells, coupled with the fact there are far more antigen sites on a Red Blood Cell, meaning more antibody can attach, means that the Red Cells will generally preferentially get removed from circulation rather than the platelets, allowing the platelets to remain in circulation. 

Given this mechanism, it is not only possible, but likely that the patient can experience a level extravascular hemolysis leading to a mild decrease in Hemoglobin/Hematocrit levels. It's important to get a baseline, and continue to monitor these levels after administration. A drop of 1-2 grams of Hgb is possible over a few days post administration. This is also why it's important to ensure there aren't other hemolytic processes taking place beforehand (like hemolytic anemia). If a patients Hgb drops too much, it is thought that they should receive Rh negative blood for the time being, to lessen the amount of hemolysis taking place, ensuring the blood remains in circulation unscathed. 

Despite these effects, use of RhIG is often quicker to infuse than IVIG, less volume than IVIG, sometimes longer duration of action when compared to IVIG, cheaper than IVIG, and a much more limited donor exposure than IVIG. 

Have you ever seen RhIG used in such circumstances?

Emergent FFP for Angioedema?

You get a call from an ER nurse that they new FFP emergently on a patient in the ER. The patient's tongue and face is swelling to the point of respiratory compromise. You don't have any blood type on file so you tell the nurse, and decide that it's so emergent that you'll have to thaw AB plasma and give it emergently. 

Macroglossia with crenations along the margins and loss of papillae on dorsum surface of the tongueWhat was happening to this patient? Why was this such an emergency? What is FFP going to do to help this patient in this situation?

Angiotensin Converting Enzyme (ACE)

 Millions of people in the world have diagnosed hypertension and may be prescribed an Angiotensin Converting Enzyme (ACE) inhibitors to control their elevated blood pressure. An uncommon side effect of ACE inhibitors includes angioedema, in which fluid buildup and swelling occurs underneath the skin in certain areas. Inhibiting Angiotensin Converting Enzyme can lead to a build up of an enzyme known as bradykinin, which is a potent vasodilator, but also leads to increased vascular and capillary permeabilty. This allows fluids to leave the space they should occupy and accumulate in other areas in which they shouldn't. This effect is known as ACE inhibitor-induced angioedema or ACEI-IAE.

ACEI-IAE typically presents as an emergency as airways and respiratory systems can quickly become compromised by excessive tongue, face, neck, etc., swelling. Initial treatment will include discontinuation of the drug, and potentially antihistamines, steroids, epinephrine, IVIG, etc. This may not work for all patients, however. 

How Does FFP Help with Angioedema?

FFP has been used successfully in patients who do not respond to other treatments. Some patients respond quite rapidly after FFP transfusion and regain respiratory control. The idea behind FFP administration is that FFP contains ACE, sometimes referred to as Kininase II, as it's an enzyme that can break down Bradykinin. This immediate addition of Kininase II from FFP transfusion helps to breakdown the excessive bradykinin that has accumulated due to ACE inhibitor use. This is why so many patients will see a very rapid improvement post FFP administration. 

Blocked D Phenomenon

Why would an Rh positive baby type as Rh negative?

Intrauterine transfusion? Sure that's possible. 

This specific scenario describes more of an immunologic basis for mistyping.

Enter...the Blocked D phenomenon. It is something very rarely seen in Blood Banks, especially these days with ever increasing sensitivity of reagents, but it can still happen. 

The Blocked D phenomenon may occur when a mother has created a strong IgG based allo-Anti-D and bears an Rh positive child. It is generally seen in fairly severe cases of HDFN. 

A sample experiencing the blocked D phenomenon will type as Rh negative, and essentially always have a positive IgG DAT. A subsequent elution would show the maternal Anti-D coating the Red Cells of the baby. The red cells type as Rh negative because maternal Anti-D is blanketing the RhD antigens on the Red Cells, blocking the REAGENT IgM Anti-D from agglutinating the cells. As a result, a false negative Rh testing occurs. With a positive IgG DAT, it would not be possible to perform a Weak D (Du) without treating the cells either, as Weak D testing is performed at the AHG (Coombs) phase. 

Cord Blood Evaluations generally arrive to the blood bank as a battery of Blood Type and Direct Coombs testing. This is why it is important to finish all testing prior to resulting. If the blood type was resulted before the DAT was completed, you may be inadvertently reporting erroneous results to the patient's Blood Bank file and chart. 

How to remedy this?

Generally you would need to perform an elution, such as an acid glycine elution, to remove the bound IgG from the neonates Red Cells. Once removed, and you can prove the antibody is removed by perform another DAT to make sure the IgG is now negative, you can retest the red cells for the D antigen using your monoclonal typing reagents. You may now perform a Weak D test as well, since the DAT is no longer IgG positive. 

How many of you have seen this phenomenon? While rare, it has real implications in the Blood Bank and for proper patient care. Not realizing the phenomenon taking place, can result in a delay of care. A newborn exhibiting this phenomenon may need to receive an exchange transfusion to remove their Red Cells and replenish with Rh negative cells until the maternal antibody is no longer reacting. If the phenomenon is not noticed at first, and the baby is resulted as Rh negative, it will change the clinical picture for the physician and make it more difficult for them to arrive at a diagnosis of HDFN and treat at a earlier point in time. 

Fat Embolism Syndrome in Sickle Cell Disease

Sickle cells
Sickle Cells on a peripheral blood smear

 Blood Banks are no stranger to patients with Sickle Cell Anemia. Many patients are chronically transfused, and many of us have been there for emergent Red Blood Cell exchanges due to acute chest, stroke, etc. What you might not have been a part of is a Sickle Cell patient experiencing Fat Embolism Syndrome. 

What is a Fat Embolism?

A fat embolism is exactly as it sounds, it's fat or globules of fat that for one reason or another enter the bloodstream circulation and act as a embolism (vasculature occlusion caused by a clot or similar). While not common, fat embolisms are usually seen in trauma with orthopedic / long bone fractures, such as tibia, fibula, femur, pelvis, etc. It can also be seen in patients with pancreatitis. 

Fat Embolism Syndrome in Sickle Cell patients

Certain populations of Sickle Cell patients may be at risk for Fat Embolisms as well. 

Fat Embolism Syndrome describes a situation in which Bone Marrow Necrosis occurs as a result of the patients Sickle Cell Disease. The necrosis is not fully understood but it's hypothesized that the microvasculature in the bone marrow may become occluded, leading to cell damage and death. As the Bone Marrow is necrosed, it is thought that this could lead to fat emboli being released into circulation, causing occlusion of vessels. Another theory proposes that fat globules released into circulation get broken down into toxic metabolites leading to a pro-inflammatory state, as evidenced by increased levels of CRP, cytokines, and free fatty acids in serum. These metabolites can be responsible for many of the symptoms seen in Fat Embolism Syndrome. 

Patients may have shortness of breath/respiratory distress, tachycardia, neurologic changes from confusion up to coma, petechial rash, pain, fever, hepatic damage (with resulting jaundice), decreased urine output, etc. 

Interestingly, patient's with more severe homozygous Sickle Cell Disease (HgbSS) are less likely to experience Fat Embolism Syndrome. Heterozygous Sickle Cell Disease such as HgbSC or HbS/ß-Thalassemia has a higher likelihood of exhibiting Fat Embolism Syndrome propensity. The thought behind this is that with heterozygous Sickle Cell Disease, patients tend to have a higher baseline hematocrit, and thus have a higher blood viscosity than that of a HgbSS patient whose hematocrits tend to trend on the lower end. This increased viscosity can lead to decreased perfusion and thus more damage, causing increased necrosis. HgbSC patients tend to have increased inflammatory issues as well, compared to their HgbSS counterparts.

Fat Embolism Syndrome Treatment with Apheresis

The Apheresis department plays a role in helping to treat Fat Embolism Syndrome. Essentially, the first line treatment of Fat Embolism Syndrome caused by Bone Marrow Necrosis in Sickle Cell Disease is to perform a Red Blood Cell exchange. This helps to remove the sickled cells that may be assisting in causing occlusions along side of the fat globules, but based on density, should also remove a portion of the fat globules as well. 

Additionally, there is reason to believe that following up with a plasma exchange could be beneficial in treating Fat Embolism Syndrome. In some patients, RBC exchange is not enough. This study explores this idea. Given that there may be a biochemical component to Fat Embolism Syndrome, such as the increased inflammatory mediators, cytokines, free fatty acids, toxic lipid metabolites, etc., it makes sense that plasmapheresis would be beneficial in removing these from the plasma.

Have you come across a patient with FES?